Votumumab Biosimilar - Research Grade

Human

CTAA16

5mg/ml

IgG3 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

CTAA16 is a tumor-associated antigen explored as a targeting epitope in oncology and tumor-imaging research. Offered as an unconjugated, non-therapeutic analog of votumumab, this recombinant human IgG3 antibody binds the CTAA16 antigen and is supplied strictly for research use only (RUO). It is purified to a low-endotoxin standard suitable for in vivo work and manufactured in scalable milligram-to-gram quantities to serve bulk and high-throughput laboratories. Researchers apply it in antigen-binding assays, in vitro tumor-cell screening, control reagents, and preclinical tumor-targeting models, with no clinical or therapeutic application implied.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks